FindTrial
Sign In

Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.

Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005546-20-NL
Enrollment
Unknown
Registered
2007-10-10
Start date
2008-02-01
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension mild renal insufficiency

Interventions

Trade Name: Crestor Product Name: Rosuvastatine Product Code: ZD4522 Pharmaceutical Form: Tablet CAS Number: 287714414 Current Sponsor code: ZD4522 Other descriptive name: ROSUVASTATIN Concentration u

Sponsors

academisch ziekenhuis Maastricht
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: hypertension (without medication BP >140/90 mmHg and 4,5 mmol/l BMI between 18 and 30 kg/m2 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: diabetes mellitus contra-indication for use of an angiotensin-II-receptorblocker or statin

Design outcomes

Primary

MeasureTime frame
Main Objective: To determine the relation between systemic effects of ADMA and mild renal dysfunction. ;Secondary Objective: -;Primary end point(s): forearm blood flow—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026